{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-25-000051","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.698252+00:00","generated_at":"2026-05-25T19:17:35.183703+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics discontinues BEACON-IPF Phase 2b trial; reports Q4 2024 net loss of $49.7M","bullets":["BEACON-IPF discontinued after DSMB and outside expert panel recommendation due to imbalance in IPF-related adverse events; early efficacy on FVC observed.","Q4 2024 net loss of $49.7M vs $41.1M in Q4 2023; R&D expenses increased to $38.8M from $33.2M.","Cash, cash equivalents, restricted cash and short-term investments of $357.2M as of Dec 31, 2024; sufficient for 12+ months.","Appointed Delphine Imbert, Ph.D. as Chief Technical Officer, previously at Chinook Therapeutics.","Phase 1 trial of PLN-101095 in solid tumors continues; interim data from first three dose cohorts expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-25-000051","json":"https://secwatch.observer/filing/0001746473-25-000051.json","markdown":"https://secwatch.observer/filing/0001746473-25-000051.md","text":"https://secwatch.observer/filing/0001746473-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000051/0001746473-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647325000051/plrx-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T19:17:35.183703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}